CANA/PHEN Aids Weight Loss in Obese Without Type 2 Diabetes

Share this content:
CANA/PHEN Aids Weight Loss in Obese Without Type 2 Diabetes
CANA/PHEN Aids Weight Loss in Obese Without Type 2 Diabetes

THURSDAY, March 23, 2017 (HealthDay News) -- For obese or overweight individuals without type 2 diabetes, coadministration of canagliflozin (CANA) and phentermine (PHEN) is associated with considerable weight loss and is well tolerated, according to a study published online March 13 in Diabetes Care.

Priscilla Hollander, M.D., Ph.D., from the Baylor University Medical Center in Dallas, and colleagues examined the efficacy and safety of coadministration of CANA and PHEN compared with placebo (PBO) and CANA or PHEN monotherapy in a randomized trial involving 335 individuals who were obese or overweight without type 2 diabetes. Participants were randomly allocated to receive PBO, CANA, PHEN, or coadministration of CANA/PHEN once daily.

The researchers found that, compared with PBO, CANA/PHEN coadministration provided superior weight loss from baseline at week 26 (least squares mean difference, −6.9 percent; P < 0.001). Compared with PBO, CANA/PHEN also provided superior achievement of weight loss ≥5 percent and reduction in systolic blood pressure. CANA/PHEN was generally well tolerated, with a consistent safety and tolerability profile relative to that of the individual components.

"CANA/PHEN produced meaningful reductions in body weight and was generally well tolerated in individuals who were overweight or obese without type 2 diabetes," the authors write. "Further studies are warranted to evaluate potential use of this combination for long-term weight management."

Several authors disclosed financial ties to pharmaceutical companies, including Janssen, which developed canagliflozin in collaboration with Mitsubishi Tanabe Pharma Corporation.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Plan to Relax Coal-Fired Power Plant Rules Could Up Mortality

Plan to Relax Coal-Fired Power Plant Rules Could ...

EPA predicts between 470 and 1,400 premature deaths a year by 2030

FDA Extends EpiPen Expiration Dates to Tackle Shortage

FDA Extends EpiPen Expiration Dates to Tackle Shortage

Shortages due to factors such as supply disruptions and manufacturer issues

USPSTF Updates Guidance for Cervical Cancer Screening

USPSTF Updates Guidance for Cervical Cancer Screening

Cytology recommended every three years from age 21; different screening options from age 30 to 65

is free, fast, and customized just for you!




Already a member?

Sign In Now »